IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Purchased by Assetmark Inc.

Assetmark Inc. boosted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 83.4% in the 4th quarter, Holdings Channel reports. The firm owned 33,804 shares of the company’s stock after purchasing an additional 15,377 shares during the period. Assetmark Inc.’s holdings in IDEXX Laboratories were worth $13,976,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Insight Wealth Strategies LLC grew its stake in shares of IDEXX Laboratories by 230.5% in the fourth quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company’s stock worth $4,174,000 after acquiring an additional 7,041 shares in the last quarter. Larson Financial Group LLC grew its stake in shares of IDEXX Laboratories by 17,238.5% in the third quarter. Larson Financial Group LLC now owns 2,254 shares of the company’s stock worth $1,139,000 after acquiring an additional 2,241 shares in the last quarter. Quest Partners LLC grew its stake in shares of IDEXX Laboratories by 4,059.4% in the third quarter. Quest Partners LLC now owns 2,870 shares of the company’s stock worth $1,450,000 after acquiring an additional 2,801 shares in the last quarter. Crystal Rock Capital Management grew its stake in shares of IDEXX Laboratories by 90.0% in the third quarter. Crystal Rock Capital Management now owns 9,005 shares of the company’s stock worth $4,550,000 after acquiring an additional 4,265 shares in the last quarter. Finally, Victory Capital Management Inc. grew its stake in shares of IDEXX Laboratories by 3.4% in the third quarter. Victory Capital Management Inc. now owns 142,628 shares of the company’s stock worth $72,059,000 after acquiring an additional 4,696 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Activity at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is owned by corporate insiders.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $429.03 on Friday. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $574.94. The stock has a market cap of $34.89 billion, a PE ratio of 40.21, a price-to-earnings-growth ratio of 3.41 and a beta of 1.37. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The firm has a fifty day moving average price of $437.06 and a 200 day moving average price of $450.19.

Wall Street Analyst Weigh In

Several research firms have commented on IDXX. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Friday. Morgan Stanley lowered their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Leerink Partners began coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price for the company. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Piper Sandler boosted their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research note on Monday, February 10th. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.